Business Wire

SpeeDx and SynGenis Partner for Custom Oligonucleotide Synthesis

Share

SpeeDx Pty, Ltd. a developer of innovative molecular diagnostic solutions announced investment in SynGenis Pty Ltd., an experienced oligonucleotide manufacturer based in Western Australia. The partnership will bolster internal capacity of SpeeDx to support large-scale increases in manufacturing while developing and expanding sovereign capacity of important raw materials used in molecular diagnostics.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210927005329/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

In addition to securing local supply chain to strengthen sovereign capacity for critical diagnostics and a more robust national health infrastructure, SpeeDx investment in local industry serves to fast track the growth and reach of SynGenis in the global diagnostics market. (Graphic: Business Wire)

“We have invested considerable resources into our production scale-up processes to support the increase in testing seen as a result of the global pandemic,” said Tom Lin, SpeeDx Director of Global Operations. “Enhancing our access to quality raw materials ensures we remain committed to maintaining supply chain security for our customers worldwide.”

The increased demand for COVID-19 diagnostics has in turn increased global demand for the oligonucleotide raw materials that form the basis of molecular diagnostic products. In addition to this supply chain burden, reduced flights and increased customs challenges entering Australia has complicated freight and delivery times from overseas suppliers. SpeeDx investment in local oligonucleotide manufacturing reduces supply chain risk and develops stronger sovereign capacity for critical diagnostics for a more robust national health infrastructure.

“As Australia’s experienced commercial oligonucleotide manufacturer with significant expertise, we are delighted to have this strategic partnership to supply custom oligonucleotides with highest quality and fast turnaround time,” said Rakesh Veedu, SynGenis Founder and Managing Director. SynGenis Chairman Steve Arnott said “The partnership with SpeeDx is a strong vote of confidence in the capability and capacity of Syngenis staff and operations and provides a significant platform for our future development.

In addition to securing local supply chain, SpeeDx investment in local industry serves to fast track the growth and expand the reach of SynGenis in the global diagnostic market.

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin, Texas and London, UK, with distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com

About SynGenis

Founded in 2020, SynGenis is an Australian oligonucleotide manufacturing company with excellent facilities based in Bentley Technology Park. SynGenis specializes in the production and supply of high-quality oligonucleotides including DNA, RNA and modified oligonucleotides for use in RNA therapeutics, diagnostics and drug delivery applications. With our expertise in oligonucleotide synthesis chemistry and state-of-the-art equipments, we support our customers from the R&D phase right through to commercial production. For more information on SynGenis please see: https://www.syngenis.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Contacts for SpeeDx:
Madeline O’Donoghue
+61 2 9209 4170
madelineo@speedx.com.au

Contacts for SynGenis:
Sofie De Meyer
+61 491 711 542
sofie@syngenis.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

O-RAN ALLIANCE Announces New Specifications, 3 rd Global Plugfest and New Demonstrations of O-RAN Technology22.10.2021 09:36:00 CEST | Press release

O-RAN ALLIANCE has released another set of technical specifications for open RAN published since July 2021. Initial versions of nine technical specifications comprise: O-RAN Non-Real-Time RAN Intelligent Controller (RIC) Architecture Near-Real-Time RIC and E2 Interface: Use Cases and Requirements v1.0 O-RAN E2 Service Model: RAN Control (E2SM-RC) v1.0 O-RAN O1 Interface specification for O-CU-UP and O-CU-CP towards the Service Management and Orchestration (SMO) framework O-RAN Acceleration Abstraction Layer FEC Profiles Infrastructure management services of the O2 interface O-Cloud Notification API Specification for Event Consumers O-RAN Xhaul Transport Testing Specification O-RAN Security Requirements Specifications Another 39 technical documents bring extensions and new features to the existing specifications. All new specifications will soon be available on our website. To learn more, please read our blog post. 3rd O-RAN ALLIANCE Global Plugfest Underway with 77 companies at 7 venue

Servier announces outcome from the primary analysis of the Phase III SOLSTICE trial assessing LONSURF ® (trifluridine/tipiracil) + bevacizumab in a 1 st line setting for patients with unresectable mCRC non-eligible for intensive therapy22.10.2021 09:00:00 CEST | Press release

Servier, a global independent pharmaceutical group, announced today that the primary objective (progression free survival) of the Phase III SOLSTICE trial has not been met. SOLSTICE was designed to evaluate the superiority of LONSURF® (trifluridine/tipiracil) + bevacizumab over capecitabine + bevacizumab in 1st line unresectable metastatic colorectal cancer (mCRC) in patients non-eligible for intensive therapy. The trial will continue as planned given that no deleterious effects and no new safety issues have been raised in either study arm. Data from the primary analysis will be presented at an upcoming medical congress. “We remain committed to improving outcomes in mCRC and we will continue to follow patients as planned in order to perform the main secondary endpoint analysis on overall survival in 2023,” said Patrick Therasse, M.D., Ph. D., Head of Late Stage and Life Cycle Management, and Deputy Head Oncology and Immuno-Oncology Therapeutic Area, Servier. “The clinical value of LONS

FEELM Issues Press Statement on FDA’s First Vaping Product Authorization22.10.2021 08:03:00 CEST | Press release

FEELM made the following statement regarding the FDA’s first vaping product authorization: On Oct 12, 2021, the U.S Food and Drug Administration (FDA) has granted marketing orders for Vuse Solo, closed electronic nicotine delivery system (ENDS) and accompanying tobacco-flavored e-liquid pods of R.J.Reynolds Vapor, allowing the products to be legally sold in the United States. It is the first set of ENDS products authorized by the FDA through the Premarket Tobacco Product Application (PMTA), marking a milestone for the global vaping regulations. It sends a positive message to the global atomization industry for it is the first time that a vaping product is authorized by a health regulator, indicating that FDA has embraced vaping’s potential to improve public health. The scientific data submitted by R.J.Reynolds Vapor has demonstrated the health benefits of Vuse tobacco-flavored ENDS. According to FDA, “under the PMTA pathway, manufacturers must demonstrate to the agency that marketing o

Pegasus Digital Mobility Acquisition Corp. Announces Pricing of $200,000,000 Initial Public Offering22.10.2021 04:58:00 CEST | Press release

Pegasus Digital Mobility Acquisition Corp. (the “Company”), a special purpose acquisition company, announced today that it priced its initial public offering (“IPO”) of 20,000,000 units at a price of $10.00 per unit. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share. The units will be listed on the New York Stock Exchange (the “NYSE”) and trade under the ticker symbol “PGSS.U” beginning on October 22, 2021. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the NYSE under the symbols “PGSS” and “PGSS.WS,” respectively. The initial public offering is expected to close on October 26, 2021, subject to customary closing conditions. Barclays Capital Inc. is serving as the sole book-running manager for the offering and EarlyBirdCapital, Inc., Ladenburg Thalmann &

The Spotlight on Iceland’s Capital City Shines Even Brighter With the Arrival of The Reykjavik EDITION21.10.2021 17:30:00 CEST | Press release

A flourishing culinary hotspot with cool cafés, a rollicking nightlife and an epic music scene, the spotlight is shining brightly on Iceland’s hip capital city and, with typical finesse, the arrival of The Reykjavik EDITION further cements EDITION Hotels' uncanny ability to land in just the right place at the right time. “Reykjavik is a really cool, young city -perfect for our brand,” says Ian Schrager, the visionary pioneer of the boutique hotel concept, PUBLIC and EDITION creator. “We think this is Reykjavik’s time and we’re right here at the very heart of it and at the perfect time.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021005764/en/ The Reykjavik EDITION (Photo: Business Wire) Opening in preview on November 9th, 2021, The Reykjavik EDITION will set a new standard as the city’s first truly luxury hotel experience, combining the best of the Icelandic capital with the personal, intimate and individual experienc

MediaTek Selected to Power Vewd for Automotive Platform21.10.2021 16:41:00 CEST | Press release

Vewd, the leading provider of OTT software solutions, today announced that MediaTek’s Autus I20 (MT2712) chipset was selected as the first reference platform to power Vewd for Automotive, a white-labeled, cloud-managed content aggregation and monetization solution for in-vehicle infotainment equipment providers and car manufacturers. MediaTek’s customer base, streaming ecosystem partnerships, and strong technical capabilities make it the strongest supplier to meet the needs of car manufacturers. Together, Vewd and MediaTek will target Strategy Analytics’ estimated 70 million connected cars on the road by 2025. Vewd for Automotive solves key rear-seat content challenges facing manufacturers through a turnkey solution ready for deployment. For manufacturers, content in the car represents an increasing consumer demand, along with the demand for connectivity that provides additional after-sale branding and revenue opportunities. By partnering with content providers, manufacturers can enabl

Biognosys to Present Major Scientific and Technological Advances at the ASMS 2021 Mass Spectrometry Conference21.10.2021 16:00:00 CEST | Press release

Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, today announced they will be presenting major scientific and technological advances on their proprietary proteomics research services, software, and kits at the American Society for Mass Spectrometry (ASMS) Annual Conference from October 31st to November 4th in Philadelphia (USA). Biognosys will present a record number of 3 oral presentations, 10 scientific posters, 2 poster collaborations, 1 workshop panel, and 2 Spectronaut™ breakfast seminars. In addition, their team of scientific experts will be present at booth #224 to answer questions and demo software. Further demo sessions will be offered at the Bruker Daltonics booth #719. Collectively, this presence demonstrates Biognosys’ significant contributions to transforming life science and clinical research with next-generation proteomics, particularly in the areas of plasma proteomics, immunopeptidomics, and proteomics data analysis. Lukas Re

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom